Plasma FGF21 Levels Are Not Associated with Weight Loss or Improvements in Metabolic Health Markers upon 12 Weeks of Energy Restriction : Secondary Analysis of an RCT

Recent studies suggest that circulating fibroblast growth factor 21 (FGF21) may be a marker of metabolic health status. We performed a secondary analysis of a 12-week randomized controlled trial to investigate the effects of two energy restriction (ER) diets on fasting and postprandial plasma FGF21 levels, as well as to explore correlations of plasma FGF21 with metabolic health markers, (macro)nutrient intake and sweet-taste preference. Abdominally obese subjects aged 40–70 years (n = 110) were randomized to one of two 25% ER diets (high-nutrient-quality diet or low-nutrient-quality diet) or a control group. Plasma FGF21 was measured in the fasting state and 120 min after a mixed meal. Both ER diets did not affect fasting or postprandial plasma FGF21 levels despite weight loss and accompanying health improvements. At baseline, the postprandial FGF21 response was inversely correlated to fasting plasma glucose (ρ = −0.24, p = 0.020) and insulin (ρ = −0.32, p = 0.001), HOMA-IR (ρ = −0.34, p = 0.001), visceral adipose tissue (ρ = −0.24, p = 0.046), and the liver enzyme aspartate aminotransferase (ρ = −0.23, p = 0.021). Diet-induced changes in these markers did not correlate to changes in plasma FGF21 levels upon intervention. Baseline higher habitual polysaccharide intake, but not mono- and disaccharide intake or sweet-taste preference, was related to lower fasting plasma FGF21 (p = 0.022). In conclusion, we found no clear evidence that fasting plasma FGF21 is a marker for metabolic health status. Circulating FGF21 dynamics in response to an acute nutritional challenge may reflect metabolic health status better than fasting levels.

Saved in:
Bibliographic Details
Main Authors: Gijbels, Anouk, Schutte, Sophie, Esser, Diederik, Michielsen, Charlotte C.J.R., Siebelink, Els, Mars, Monica, Mensink, Marco, Afman, Lydia A.
Format: Article/Letter to editor biblioteca
Language:English
Subjects:FGF21, caloric restriction, dietary intervention, energy restriction, fibroblast growth factor 21, liver fat, metabolic health, obesity, overweight, weight loss,
Online Access:https://research.wur.nl/en/publications/plasma-fgf21-levels-are-not-associated-with-weight-loss-or-improv
Tags: Add Tag
No Tags, Be the first to tag this record!
id dig-wur-nl-wurpubs-606901
record_format koha
spelling dig-wur-nl-wurpubs-6069012024-10-02 Gijbels, Anouk Schutte, Sophie Esser, Diederik Michielsen, Charlotte C.J.R. Siebelink, Els Mars, Monica Mensink, Marco Afman, Lydia A. Article/Letter to editor Nutrients 14 (2022) 23 ISSN: 2072-6643 Plasma FGF21 Levels Are Not Associated with Weight Loss or Improvements in Metabolic Health Markers upon 12 Weeks of Energy Restriction : Secondary Analysis of an RCT 2022 Recent studies suggest that circulating fibroblast growth factor 21 (FGF21) may be a marker of metabolic health status. We performed a secondary analysis of a 12-week randomized controlled trial to investigate the effects of two energy restriction (ER) diets on fasting and postprandial plasma FGF21 levels, as well as to explore correlations of plasma FGF21 with metabolic health markers, (macro)nutrient intake and sweet-taste preference. Abdominally obese subjects aged 40–70 years (n = 110) were randomized to one of two 25% ER diets (high-nutrient-quality diet or low-nutrient-quality diet) or a control group. Plasma FGF21 was measured in the fasting state and 120 min after a mixed meal. Both ER diets did not affect fasting or postprandial plasma FGF21 levels despite weight loss and accompanying health improvements. At baseline, the postprandial FGF21 response was inversely correlated to fasting plasma glucose (ρ = −0.24, p = 0.020) and insulin (ρ = −0.32, p = 0.001), HOMA-IR (ρ = −0.34, p = 0.001), visceral adipose tissue (ρ = −0.24, p = 0.046), and the liver enzyme aspartate aminotransferase (ρ = −0.23, p = 0.021). Diet-induced changes in these markers did not correlate to changes in plasma FGF21 levels upon intervention. Baseline higher habitual polysaccharide intake, but not mono- and disaccharide intake or sweet-taste preference, was related to lower fasting plasma FGF21 (p = 0.022). In conclusion, we found no clear evidence that fasting plasma FGF21 is a marker for metabolic health status. Circulating FGF21 dynamics in response to an acute nutritional challenge may reflect metabolic health status better than fasting levels. en application/pdf https://research.wur.nl/en/publications/plasma-fgf21-levels-are-not-associated-with-weight-loss-or-improv 10.3390/nu14235061 https://edepot.wur.nl/583692 FGF21 caloric restriction dietary intervention energy restriction fibroblast growth factor 21 liver fat metabolic health obesity overweight weight loss https://creativecommons.org/licenses/by/4.0/ https://creativecommons.org/licenses/by/4.0/ Wageningen University & Research
institution WUR NL
collection DSpace
country Países bajos
countrycode NL
component Bibliográfico
access En linea
databasecode dig-wur-nl
tag biblioteca
region Europa del Oeste
libraryname WUR Library Netherlands
language English
topic FGF21
caloric restriction
dietary intervention
energy restriction
fibroblast growth factor 21
liver fat
metabolic health
obesity
overweight
weight loss
FGF21
caloric restriction
dietary intervention
energy restriction
fibroblast growth factor 21
liver fat
metabolic health
obesity
overweight
weight loss
spellingShingle FGF21
caloric restriction
dietary intervention
energy restriction
fibroblast growth factor 21
liver fat
metabolic health
obesity
overweight
weight loss
FGF21
caloric restriction
dietary intervention
energy restriction
fibroblast growth factor 21
liver fat
metabolic health
obesity
overweight
weight loss
Gijbels, Anouk
Schutte, Sophie
Esser, Diederik
Michielsen, Charlotte C.J.R.
Siebelink, Els
Mars, Monica
Mensink, Marco
Afman, Lydia A.
Plasma FGF21 Levels Are Not Associated with Weight Loss or Improvements in Metabolic Health Markers upon 12 Weeks of Energy Restriction : Secondary Analysis of an RCT
description Recent studies suggest that circulating fibroblast growth factor 21 (FGF21) may be a marker of metabolic health status. We performed a secondary analysis of a 12-week randomized controlled trial to investigate the effects of two energy restriction (ER) diets on fasting and postprandial plasma FGF21 levels, as well as to explore correlations of plasma FGF21 with metabolic health markers, (macro)nutrient intake and sweet-taste preference. Abdominally obese subjects aged 40–70 years (n = 110) were randomized to one of two 25% ER diets (high-nutrient-quality diet or low-nutrient-quality diet) or a control group. Plasma FGF21 was measured in the fasting state and 120 min after a mixed meal. Both ER diets did not affect fasting or postprandial plasma FGF21 levels despite weight loss and accompanying health improvements. At baseline, the postprandial FGF21 response was inversely correlated to fasting plasma glucose (ρ = −0.24, p = 0.020) and insulin (ρ = −0.32, p = 0.001), HOMA-IR (ρ = −0.34, p = 0.001), visceral adipose tissue (ρ = −0.24, p = 0.046), and the liver enzyme aspartate aminotransferase (ρ = −0.23, p = 0.021). Diet-induced changes in these markers did not correlate to changes in plasma FGF21 levels upon intervention. Baseline higher habitual polysaccharide intake, but not mono- and disaccharide intake or sweet-taste preference, was related to lower fasting plasma FGF21 (p = 0.022). In conclusion, we found no clear evidence that fasting plasma FGF21 is a marker for metabolic health status. Circulating FGF21 dynamics in response to an acute nutritional challenge may reflect metabolic health status better than fasting levels.
format Article/Letter to editor
topic_facet FGF21
caloric restriction
dietary intervention
energy restriction
fibroblast growth factor 21
liver fat
metabolic health
obesity
overweight
weight loss
author Gijbels, Anouk
Schutte, Sophie
Esser, Diederik
Michielsen, Charlotte C.J.R.
Siebelink, Els
Mars, Monica
Mensink, Marco
Afman, Lydia A.
author_facet Gijbels, Anouk
Schutte, Sophie
Esser, Diederik
Michielsen, Charlotte C.J.R.
Siebelink, Els
Mars, Monica
Mensink, Marco
Afman, Lydia A.
author_sort Gijbels, Anouk
title Plasma FGF21 Levels Are Not Associated with Weight Loss or Improvements in Metabolic Health Markers upon 12 Weeks of Energy Restriction : Secondary Analysis of an RCT
title_short Plasma FGF21 Levels Are Not Associated with Weight Loss or Improvements in Metabolic Health Markers upon 12 Weeks of Energy Restriction : Secondary Analysis of an RCT
title_full Plasma FGF21 Levels Are Not Associated with Weight Loss or Improvements in Metabolic Health Markers upon 12 Weeks of Energy Restriction : Secondary Analysis of an RCT
title_fullStr Plasma FGF21 Levels Are Not Associated with Weight Loss or Improvements in Metabolic Health Markers upon 12 Weeks of Energy Restriction : Secondary Analysis of an RCT
title_full_unstemmed Plasma FGF21 Levels Are Not Associated with Weight Loss or Improvements in Metabolic Health Markers upon 12 Weeks of Energy Restriction : Secondary Analysis of an RCT
title_sort plasma fgf21 levels are not associated with weight loss or improvements in metabolic health markers upon 12 weeks of energy restriction : secondary analysis of an rct
url https://research.wur.nl/en/publications/plasma-fgf21-levels-are-not-associated-with-weight-loss-or-improv
work_keys_str_mv AT gijbelsanouk plasmafgf21levelsarenotassociatedwithweightlossorimprovementsinmetabolichealthmarkersupon12weeksofenergyrestrictionsecondaryanalysisofanrct
AT schuttesophie plasmafgf21levelsarenotassociatedwithweightlossorimprovementsinmetabolichealthmarkersupon12weeksofenergyrestrictionsecondaryanalysisofanrct
AT esserdiederik plasmafgf21levelsarenotassociatedwithweightlossorimprovementsinmetabolichealthmarkersupon12weeksofenergyrestrictionsecondaryanalysisofanrct
AT michielsencharlottecjr plasmafgf21levelsarenotassociatedwithweightlossorimprovementsinmetabolichealthmarkersupon12weeksofenergyrestrictionsecondaryanalysisofanrct
AT siebelinkels plasmafgf21levelsarenotassociatedwithweightlossorimprovementsinmetabolichealthmarkersupon12weeksofenergyrestrictionsecondaryanalysisofanrct
AT marsmonica plasmafgf21levelsarenotassociatedwithweightlossorimprovementsinmetabolichealthmarkersupon12weeksofenergyrestrictionsecondaryanalysisofanrct
AT mensinkmarco plasmafgf21levelsarenotassociatedwithweightlossorimprovementsinmetabolichealthmarkersupon12weeksofenergyrestrictionsecondaryanalysisofanrct
AT afmanlydiaa plasmafgf21levelsarenotassociatedwithweightlossorimprovementsinmetabolichealthmarkersupon12weeksofenergyrestrictionsecondaryanalysisofanrct
_version_ 1812998788215734272